Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Simple item page
dc.contributor.authorTurkova, Anna
dc.contributor.authorBwakura-Dangarembizi, Mutsa F.
dc.contributor.authorKekitiinwa, Adeodata R.
dc.contributor.authorLugemwa, Abbas
dc.contributor.authorAhimbisibwe, Grace Miriam
dc.contributor.authorBurger, David M.
dc.date.accessioned2025-02-19T09:56:18Z
dc.date.available2025-02-19T09:56:18Z
dc.date.issued2022-07-19
dc.description.abstractChildren with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
dc.identifier.citationTurkova, A., Waalewijn, H., Chan, M. K., Bollen, P. D., Bwakura-Dangarembizi, M. F., Kekitiinwa, A. R., ... & Greetanukroh, P. (2022). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. The Lancet HIV, 9(9), e627-e637.
dc.identifier.otherhttps://doi.org/10.1016/ S2352-3018(22)00160-6
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9969
dc.language.isoen
dc.publisherThe Lancet HIV
dc.titleDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS2352301822001606.pdf
Size:
698.89 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences